Keyword: Tremfya (guselkumab)
Johnson & Johnson is chasing giants in its play for psoriatic arthritis with Tremfya. Strong data could help the newcomer convince the FDA.
Eli Lilly is busy hounding Novartis’ Cosentyx with IL-17A med Taltz. In the meantime, Taltz will settle for besting an IL-23 competitor in psoriasis.
In December, J&J touted head-to-head results for Tremfya against Novartis’ Cosentyx. But now, Lilly has topped Tremfya in a contest of its own.
With longtime blockbuster Humira on the decline, AbbVie is looking to next-gen competitor Skyrizi to chip in. An OK across the pond could help.
Move over, Johnson & Johnson—AbbVie just joined the IL-23 party with a direct competitor to Tremfya, and analysts say it might just be best-in-class.
What does it take to run one of pharma’s biggest whales? As J&J CEO Alex Gorsky told Fortune, six years in the U.S. Army made all the difference.
Novartis’ Cosentyx has beaten out rivals from Eli Lilly and J&J to land a psoriasis nod in China.
To focus as what CEO Vas Narasimhan calls “a medicines company,” Novartis made a series of M&A decisions in 2018.
Sun Pharma debuts its first TV ad for psoriasis treatment Ilumya as national TV campaigns become table stakes in the crowded psoriasis category.